Key Points
- Insider sale: Eric Warren sold 7,438 Mineralys Therapeutics shares for approximately $199,859 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 16.23% to 38,400 shares. He also sold 104,124 shares in June for about $2.70 million.
- Stock and earnings: MLYS opened at $26.95, down 1%, with a $2.22 billion market capitalization. The company reported a quarterly loss of $0.47 per share, beating analysts’ expected loss of $0.51.
- Investor outlook: Institutional investors own 84.46% of the stock, while analysts maintain a “Moderate Buy” consensus and an average price target of $49.33, despite some hold and sell ratings.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider Eric Warren sold 7,438 shares of the firm's stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $26.87, for a total value of $199,859.06. Following the completion of the transaction, the insider owned 38,400 shares of the company's stock, valued at approximately $1,031,808. The trade was a 16.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Warren also recently made the following trade(s):
- On Friday, June 26th, Eric Warren sold 104,124 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.90, for a total value of $2,696,811.60.
Mineralys Therapeutics Stock Down 1.0%
Shares of NASDAQ MLYS opened at $26.95 on Wednesday. The business's 50 day moving average price is $27.08 and its 200 day moving average price is $28.07. The firm has a market cap of $2.22 billion, a P/E ratio of -13.15 and a beta of 0.66. Mineralys Therapeutics, Inc. has a 52 week low of $12.59 and a 52 week high of $47.65.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.04. As a group, research analysts expect that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.
Hedge Funds Weigh In On Mineralys Therapeutics
Several institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Mineralys Therapeutics by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company's stock valued at $271,000 after purchasing an additional 702 shares in the last quarter. Navalign LLC purchased a new stake in Mineralys Therapeutics during the fourth quarter worth $33,000. Velan Capital Investment Management LP boosted its holdings in Mineralys Therapeutics by 0.6% during the third quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company's stock worth $6,659,000 after buying an additional 1,000 shares in the last quarter. Royal Bank of Canada grew its position in Mineralys Therapeutics by 262.3% during the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock valued at $56,000 after buying an additional 1,107 shares during the period. Finally, KBC Group NV acquired a new stake in Mineralys Therapeutics during the first quarter valued at $33,000. 84.46% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on MLYS. HC Wainwright reissued a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Jefferies Financial Group reaffirmed a "hold" rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. TD Cowen started coverage on Mineralys Therapeutics in a research report on Monday, April 27th. They set a "buy" rating on the stock. Wall Street Zen lowered Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $49.33.
View Our Latest Research Report on MLYS
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
